GlassScriptPhysician profile
Jacob B Webster
NPI 1164453957
$13,383.43
in general payments reported to CMS, 2019-2025
54 companies · $1,883 in 2025
The $1,883 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,157 · 2020: $1,866 · 2021: $2,268 · 2022: $1,682 · 2023: $1,583 · 2024: $1,944 · 2025: $1,883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,403 · Education: $7.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,402.55 |
| Education | $7.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,847.14 | 2019-2025 | Vraylar, Qulipta, Linzess |
| Novo Nordisk INC | $1,736.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,271.69 | 2019-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $909.26 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $725.07 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $637.92 | 2019-2023 | Spravato, Xarelto |
| Astrazeneca Pharmaceuticals LP | $636.21 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $568.02 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $554.61 | 2019-2024 | Stiolto Respimat, Spiriva Respimat |
| Amarin Pharma, INC. | $549.98 | 2019-2023 | |
| Glaxosmithkline, LLC. | $496.10 | 2019-2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $447.18 | 2019-2024 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $376.24 | 2019-2025 | |
| Astellas Pharma US INC | $296.64 | 2019-2025 | Veozah |
| Abbott Laboratories | $262.03 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Webster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.